Drug Profile
Pamiparib companion diagnostic - Myriad Genetics
Alternative Names: BGB 290 companion diagnostic - Myriad Genetics; BGB 290-BRACAnalysis CDx®; BGB 290-myChoice® HRD; Pamiparib-BRACAnalysis CDx®; Pamiparib-myChoice® HRDLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Myriad Genetics
- Developer BeiGene; Myriad Genetics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Diagnosis) in World
- 06 Apr 2017 Clinical development in Cancer (Diagnosis) in world(unspecified route)